Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Florian Lordick et al.|The Lancet|2023Cited by 701
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Geoffrey Y. Ku, Yelena Y. Janjigian et al.|The Lancet Oncology|2023Cited by 237
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A. Reiss, Yara Abdou, Mathew G. Angelos et al.|Nature Medicine|2025Cited by 189
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M. Huffman, Samuel J. Klempner, Vasily N. Aushev et al.|JCO Precision Oncology|2022Cited by 72
Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7Ryan L. Rodriguez del Villar, Sunil Sharma, Trason Thode et al.|Cancer Research|2021Cited by 1